0000899243-21-024574.txt : 20210617 0000899243-21-024574.hdr.sgml : 20210617 20210617211547 ACCESSION NUMBER: 0000899243-21-024574 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210617 FILED AS OF DATE: 20210617 DATE AS OF CHANGE: 20210617 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gengos Andrew CENTRAL INDEX KEY: 0001563623 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40499 FILM NUMBER: 211026884 MAIL ADDRESS: STREET 1: 21900 BURBANK BOULEVARD STREET 2: 3RD FLOOR CITY: WOODLAND HILLS STATE: CA ZIP: 91367 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cyteir Therapeutics, Inc. CENTRAL INDEX KEY: 0001662244 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455429901 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SPRING STREET STREET 2: BUILDING A, SUITE 510 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 857-285-4140 MAIL ADDRESS: STREET 1: 128 SPRING STREET STREET 2: BUILDING A, SUITE 510 CITY: LEXINGTON STATE: MA ZIP: 02421 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-06-17 0 0001662244 Cyteir Therapeutics, Inc. CYT 0001563623 Gengos Andrew 128 SPRING ST, BUILDING A, SUITE 510 LEXINGTON MA 02421 0 1 0 0 Chief Business Officer Common Stock 73534 D Stock Option (Right to Buy) 1.19 2030-03-23 Common Stock 55151 D Stock Option (Right to Buy) 1.19 2030-03-23 Common Stock 147070 D Stock Option (Right to Buy) 7.09 2031-02-21 Common Stock 102927 D Includes 4,595 shares acquired upon early exercise of an option, which are subject to forfeiture until they vest. The option vests as to 75% of the underlying shares of common stock on February 24, 2023, and as to the remaining shares underlying the award in 12 equal monthly installments thereafter, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. The option vests as to 25% of the underlying shares of common stock on February 24, 2021, and as to the remaining shares underlying the award in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. The option will become exercisable as to 1/36th of the underlying shares of common stock at the end of each successive one-month period following the vesting commencement date, February 5, 2021, until the option is fully vested on the third anniversary of the vesting commencement date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. By: /s/ Andrew Gengos 2021-06-17